首页> 外文期刊>Applied immunohistochemistry and molecular morphology: AIMM >Diagnostic role of inhibin α-subunit and inhibin/activin β-subunit in adrenal cortical and medullary tumors in egyptian patients
【24h】

Diagnostic role of inhibin α-subunit and inhibin/activin β-subunit in adrenal cortical and medullary tumors in egyptian patients

机译:抑制素α亚基和抑制素/激活素β亚基在埃及肾上腺皮质和髓样肿瘤中的诊断作用

获取原文
获取原文并翻译 | 示例
           

摘要

Inhibin and activins are dimeric glycoproteins that are structurally and functionally related to transforming growth factor-β and are composed of 1 α-subunit and 1 of 2 β-subunits (βA or βB). In recent years, there has been controversy about their role in adrenal tumors and their suitability as a diagnostic/predictive marker. Inhibin α and inhibin/activin β protein expression was assessed on 47 adrenal tissue specimens by means of immunohistochemistry. Positive immunoreactivity of inhibin-α was seen in all studied hyperplastic adrenal glands, 90.9% of cortical adenomas, and 83.3% of adrenal cortical carcinomas. In contrast, the adrenomedullary neoplasms had a statistically significantly different behavior (P=0.001). We observed the negative expression of inhibin α in 85% and 80% of benign and malignant pheochromocytomas, respectively. As regards the immunoreactivity of inhibin/activin β, 80% of adrenal hyperplasias, 81.8% of cortical adenomas, and 83.3% of adrenal cortical carcinomas showed positivity. Strong-to-weak positive staining of inhibin/activin β was observed in 70% of benign pheochromocytomas, whereas malignant pheochromocytomas showed positive immunohistochemical staining in 40% of cases with weak intensity. The scoring of inhibin/activin β immunoreactivity between adrenocortical and adrenomeullary neoplasia failed to reach the significant value (P=0.1). Our results demonstrate that inhibin α had a diagnostic role, differentiating between the adrenocortical and adrenomedullary neoplasms. Moreover, inhibin/activin β might play a predictive role for malignant potential in pheochromocytoma. Further studies are warranted to determine whether they play a diagnostic/predictive role in adrenal tumors or are just surrogate markers for this group of neoplasia.
机译:抑制素和激活素是与转化生长因子-β在结构和功能上相关的二聚体糖蛋白,由1个α亚基和2个β亚基(βA或βB)中的1个组成。近年来,关于它们在肾上腺肿瘤中的作用及其作为诊断/预测标志物的适用性一直存在争议。通过免疫组织化学方法评估了47个肾上腺组织标本中抑制素α和抑制素/激活素β蛋白的表达。在所有研究过的增生性肾上腺,90.9%的皮质腺瘤和83.3%的肾上腺皮质癌中均可见抑制素-α的阳性免疫反应性。相反,肾上腺髓质肿瘤的行为有统计学差异(P = 0.001)。我们观察到分别在85%和80%的良性和恶性嗜铬细胞瘤中抑制素α的阴性表达。关于抑制素/激活素β的免疫反应性,肾上腺增生的80%,皮质腺瘤的81.8%和肾上腺皮质癌的83.3%显示阳性。在70%的良性嗜铬细胞瘤中观察到了抑制蛋白/激活素β的强至弱阳性染色,而在40%强度较弱的病例中,恶性嗜铬细胞瘤显示了阳性免疫组织化学染色。肾上腺皮质和肾上腺髓质瘤之间抑制素/激活素β免疫反应的评分未能达到显着值(P = 0.1)。我们的结果表明,抑制素α具有诊断作用,可区分肾上腺皮质和肾上腺髓质肿瘤。此外,抑制素/激活素β可能对嗜铬细胞瘤中的恶性潜能具有预测作用。有必要进行进一步的研究,以确定它们是否在肾上腺肿瘤中发挥诊断/预测作用,还是仅仅是该组赘生物的替代标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号